Report Detail
Global Antidiabetic Drug Market - Premium Insight, Industry Trends, FPNV Positioning Matrix, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2024 (Q3 2018 Update)
- RnM2798292 |
- 14 March, 2019 |
- Global |
- 147 Pages |
- 360iResearch |
- Other
The global antidiabetic drug market is expected to grow from USD 56.93 billion 2017 to USD 81.82 billion by the end of 2024 at a Compound Annual Growth Rate (CAGR) of 5.32%.
“Changing lifestyle of people and irregular dietary habits
is one of the factors largely attributing to the growth of antidiabetic drug market globally”
The factors attributing to the growth of the market are changing lifestyle of people and irregular dietary habits, strong product pipeline of antidiabetics, globally rising prevalence of diabetes and increasing obesity among people, and increasing consumer awareness level and improved technology. However, some factors such as and prohibitive cost of insulin may hinder the market growth. The global antidiabetic drug market is expected to showcase the opportunities such as advancement in the healthcare and pharmaceutical sectors, ongoing research and development, and governments and private companies to work together for the supply of inexpensive drugs. In the near future, the market may face the possible challenges in the growth due to and wide availability of antidiabetics drugs. However, the key players in the market are putting regressive efforts to provide innovative offerings and benchmark strategies in the global antidiabetic drug market market.
On the basis of disease , the global antidiabetic drug market is studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.
On the basis of patient, the global antidiabetic drug market is studied across Adult, Geriatric, and Pediatric.
On the basis of type, the global antidiabetic drug market is studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione.
On the basis of geography, the global antidiabetic drug market is studied across Americas, (United States, Brazil, Canada, Mexico, and Argentina) Europe, Middle East & Africa, (United Kingdom, Germany, France, Saudi Arabia, United Arab Emirates, Italy, and Russia) and Asia-Pacific (China, Japan, India, and Australia).
“AstraZeneca plc: The potential growing player for the global antidiabetic drug market”
The key players profiled in the global antidiabetic drug market are AstraZeneca plc, Biocon Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Halozyme Therapeutics, Inc., Johnson & Johnson, Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Takeda Pharmaceutical Company Ltd, Tonghua Dongbao Pharmaceutical Co., Ltd., Wockhardt Limited, and sanofi-aventis U.S. LLC.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the global antidiabetic drug market.
2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the global antidiabetic drug market.
3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the global antidiabetic drug market.
4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the global antidiabetic drug market.
5. Competitive Assessment & Intelligence: Provides exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global antidiabetic drug market.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Stakeholders
2. Research & Forecasting
- 2.1. Research Methodology
- 2.1.1. Research Instruments
- 2.1.1.1. Secondary Instrument
- 2.1.1.2. Primary Instrument
- 2.1.2. Research Approaches
- 2.1.2.1. Bottom-up Approach
- 2.1.2.2. Top-down Approach
- 2.1.3. Research Reliability & Validity
- 2.1.4. Research Assumptions
- 2.1.5. Vendor Inclusion Criteria
- 2.1.1. Research Instruments
- 2.2. Forecasting Methodology
- 2.2.1. Methodology for Market Estimation & Forecasting
- 2.2.2. Significance and Importance of the Market Estimation & Forecasting
3. Executive Summary
4. Premium Insight
- 4.1. Market Connectivity
- 4.2. Market Data Feed
- 4.3. Market Vendor Ranking Analysis
- 4.4. Market Dynamics
- 4.4.1. Drivers
- 4.4.1.1. Changing lifestyle of people and irregular dietary habits
- 4.4.1.2. Strong product pipeline of antidiabetics
- 4.4.1.3. Globally rising prevalence of diabetes and increasing obesity among people
- 4.4.1.4. Increasing consumer awareness level and improved technology
- 4.4.2. Restraints
- 4.4.2.1. Prohibitive cost of Insulin
- 4.4.3. Opportunities
- 4.4.3.1. Advancement in the healthcare and pharmaceutical sectors
- 4.4.3.2. Ongoing research and development
- 4.4.3.3. Governments and private companies to work together for the supply of inexpensive drugs
- 4.4.4. Challenges
- 4.4.4.1. Wide availability of antidiabetics drugs
- 4.4.1. Drivers
- 4.5. Porter’s Five Forces Analysis
- 4.5.1. Threat of New Entrants
- 4.5.2. Threat of Substitutes
- 4.5.3. Bargaining Power of Customers
- 4.5.4. Bargaining Power of Suppliers
- 4.5.5. Industry Rivalry
5. Global Antidiabetic Drug Market, by Disease
- 5.1. Introduction
- 5.2. Diabetes Mellitus Type 1
- 5.3. Diabetes Mellitus Type 2
6. Global Antidiabetic Drug Market, by Patient
- 6.1. Introduction
- 6.2. Adult
- 6.3. Geriatric
- 6.4. Pediatric
7. Global Antidiabetic Drug Market, by Type
- 7.1. Introduction
- 7.2. Alpha-glucosidase Inhibitors
- 7.3. Biguanides
- 7.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
- 7.5. GLP-1 (Glucagon-like Peptide) Agonists
- 7.6. Insulin
- 7.6.1. Intermediate-acting Insulin
- 7.6.2. Long-acting Analog
- 7.6.3. Premixed Insulin
- 7.6.4. Rapid-acting Analog
- 7.6.5. Short-acting Analog
- 7.7. Meglitinides
- 7.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
- 7.9. Sulphonylureas
- 7.10. Thiazolidinedione
8. Global Antidiabetic Drug Market, by Geography
- 8.1. Introduction
- 8.2. Americas Antidiabetic Drug Market
- 8.2.1. Americas Antidiabetic Drug Market, by Country
- 8.2.1.1. United States
- 8.2.1.2. Brazil
- 8.2.1.3. Canada
- 8.2.1.4. Mexico
- 8.2.1.5. Argentina
- 8.2.2. Americas Antidiabetic Drug Market, by Disease
- 8.2.3. Americas Antidiabetic Drug Market, by Patient
- 8.2.4. Americas Antidiabetic Drug Market, by Type
- 8.2.1. Americas Antidiabetic Drug Market, by Country
- 8.3. Europe, Middle East & Africa Antidiabetic Drug Market
- 8.3.1. Europe, Middle East & Africa Antidiabetic Drug Market, by Country
- 8.3.1.1. United Kingdom
- 8.3.1.2. Germany
- 8.3.1.3. France
- 8.3.1.4. Saudi Arabia
- 8.3.1.5. United Arab Emirates
- 8.3.1.6. Italy
- 8.3.1.7. Russia
- 8.3.2. Europe, Middle East & Africa Antidiabetic Drug Market, by Disease
- 8.3.3. Europe, Middle East & Africa Antidiabetic Drug Market, by Patient
- 8.3.4. Europe, Middle East & Africa Antidiabetic Drug Market, by Type
- 8.3.1. Europe, Middle East & Africa Antidiabetic Drug Market, by Country
- 8.4. Asia-Pacific Antidiabetic Drug Market
- 8.4.1. Asia-Pacific Antidiabetic Drug Market, by Country
- 8.4.1.1. China
- 8.4.1.2. Japan
- 8.4.1.3. India
- 8.4.1.4. Australia
- 8.4.2. Asia-Pacific Antidiabetic Drug Market, by Disease
- 8.4.3. Asia-Pacific Antidiabetic Drug Market, by Patient
- 8.4.4. Asia-Pacific Antidiabetic Drug Market, by Type
- 8.4.1. Asia-Pacific Antidiabetic Drug Market, by Country
9. Competitive Strategic Window
- 9.1. Introduction
- 9.1.1. Leverage Zone
- 9.1.2. Vantage Zone
- 9.1.3. Speculative Zone
- 9.1.4. Bottleneck Zone
10. FPNV Positioning Matrix
- 10.1. Introduction
- 10.2. Scores
- 10.2.1. Forefront
- 10.2.2. Pathfinders
- 10.2.3. Niche
- 10.2.4. Vital
- 10.3. Business Strategy
- 10.4. Product Satisfaction
11. Competitive News Feed Analysis
12. Company Usability Profiles
- 12.1. AstraZeneca plc
- 12.2. Biocon Limited
- 12.3. Boehringer Ingelheim GmbH
- 12.4. Bristol-Myers Squibb Company
- 12.5. Eli Lilly and Company
- 12.6. Halozyme Therapeutics, Inc.
- 12.7. Johnson & Johnson
- 12.8. Merck KGaA
- 12.9. Novo Nordisk A/S
- 12.10. Oramed Pharmaceuticals Inc.
- 12.11. Pfizer Inc.
- 12.12. Takeda Pharmaceutical Company Ltd
- 12.13. Tonghua Dongbao Pharmaceutical Co., Ltd.
- 12.14. Wockhardt Limited
- 12.15. sanofi-aventis U.S. LLC
13. Appendix
- 13.1. Top Reports
- 13.2. Author Details
LIST OF TABLES (38 TABLES)
TABLE 1. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
TABLE 2. GLOBAL ANTIDIABETIC DRUG MARKET RANKING, BY VENDORS, 2017
TABLE 3. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2016 - 2024 (USD BILLION)
TABLE 4. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 5. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 6. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2016 - 2024 (USD BILLION)
TABLE 7. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 8. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 9. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 10. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2016 - 2024 (USD BILLION)
TABLE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2016 - 2024 (USD BILLION)
TABLE 21. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
TABLE 22. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2016 - 2024 (USD BILLION)
TABLE 23. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2016 - 2024 (USD BILLION)
TABLE 24. AMERICAS ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2016 - 2024 (USD BILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
TABLE 26. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2016 - 2024 (USD BILLION)
TABLE 27. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2016 - 2024 (USD BILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2016 - 2024 (USD BILLION)
TABLE 29. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
TABLE 30. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2016 - 2024 (USD BILLION)
TABLE 31. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2016 - 2024 (USD BILLION)
TABLE 32. ASIA-PACIFIC ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2016 - 2024 (USD BILLION)
TABLE 33. 360IRESEARCH SCORES FOR FOREFRONT IN ANTIDIABETIC DRUG MARKET
TABLE 34. 360IRESEARCH SCORES FOR PATHFINDERS IN ANTIDIABETIC DRUG MARKET
TABLE 35. 360IRESEARCH SCORES FOR NICHE IN ANTIDIABETIC DRUG MARKET
TABLE 36. 360IRESEARCH SCORES FOR VITAL IN ANTIDIABETIC DRUG MARKET
TABLE 37. 360IRESEARCH FPNV POSITIONING MATRIX BUSINESS STRATEGY FOR ANTIDIABETIC DRUG MARKET
TABLE 38. 360IRESEARCH FPNV POSITIONING MATRIX PRODUCT SATISFACTION FOR ANTIDIABETIC DRUG MARKET
LIST OF FIGURES (34 TABLES)
FIGURE 1. GLOBAL ANTIDIABETIC DRUG MARKET: YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ANTIDIABETIC DRUG MARKET: KEY RESEARCH METHODOLOGY
FIGURE 3. GLOBAL ANTIDIABETIC DRUG MARKET: KEY RESEARCH INSTRUMENTS
FIGURE 4. GLOBAL ANTIDIABETIC DRUG MARKET: KEY SECONDARY INSTRUMENT SOURCES
FIGURE 5. GLOBAL ANTIDIABETIC DRUG MARKET: KEY POTENTIAL RESPONDENTS
FIGURE 6. GLOBAL ANTIDIABETIC DRUG MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT
FIGURE 7. GLOBAL ANTIDIABETIC DRUG MARKET: KEY RESEARCH APPROACHES
FIGURE 8. GLOBAL ANTIDIABETIC DRUG MARKET: KEY DATA TRIANGULATION
FIGURE 9. GLOBAL ANTIDIABETIC DRUG MARKET: KEY RESEARCH ASSUMPTIONS
FIGURE 10. ANTIDIABETIC DRUG MARKET: KEY MARKET CONNECTIVITY
FIGURE 11. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, 2016 - 2024 (USD BILLION)
FIGURE 12. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DISEASE , 2017 VS 2024 (USD BILLION)
FIGURE 13. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 14. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 15. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PATIENT, 2017 VS 2024 (USD BILLION)
FIGURE 16. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ADULT, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 17. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GERIATRIC, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 18. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY PEDIATRIC, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 19. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY TYPE, 2017 VS 2024 (USD BILLION)
FIGURE 20. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 21. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY BIGUANIDES, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 22. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 23. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 24. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY INSULIN, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 25. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY MEGLITINIDES, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 26. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 27. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY SULPHONYLUREAS, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 28. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY THIAZOLIDINEDIONE, BY GEOGRAPHY, 2017 VS 2024 (USD BILLION)
FIGURE 29. GLOBAL ANTIDIABETIC DRUG MARKET SIZE, BY GEOGRAPHY, 2017 (USD BILLION)
FIGURE 30. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET, BY DISEASE , 2024
FIGURE 31. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET, BY PATIENT, 2024
FIGURE 32. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET, BY TYPE, 2024
FIGURE 33. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIDIABETIC DRUG MARKET, BY GEOGRAPHY, 2024
FIGURE 34. 360IRESEARCH FPNV POSITIONING MATRIX FOR ANTIDIABETIC DRUG MARKET
Summary:
Get latest Market Research Reports on Antidiabetic Drug . Industry analysis & Market Report on Antidiabetic Drug is a syndicated market report, published as Global Antidiabetic Drug Market - Premium Insight, Industry Trends, FPNV Positioning Matrix, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2024 (Q3 2018 Update). It is complete Research Study and Industry Analysis of Antidiabetic Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
